Cochrane · systematic review · CD012658
Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia
Mittermeier, T, Farrant, C, Wise, MR · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
7
No studies
6
Included studies
NR
No studies 6 · 46.2%Ungraded 0 · 0%Very low 2 · 15.4%Low 4 · 30.8%Moderate 1 · 7.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
LNG‐IUS compared to non‐intrauterine progestogen for endometrial hyperplasia
Population: endometrial hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regression of EH; by length of LNG‐IUS vs non‐intrauterine progestogen | OR 2.94 [2.1, 4.13] | 10 studies · 1108 participants | Moderate Downgraded: risk of bias |
Regression of EH; by length of LNG‐IUS vs non‐intrauterine progestogen | OR 3.8 [1.75, 8.23] | 1 study · 138 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Hysterectomy; histologically and non‐histologically indicated LNG‐IUS vs non‐intrauterine progestogen | OR 0.26 [0.15, 0.46] | 4 studies · 452 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects associated with hormones:Bleeding/spotting Nausea Weight gain LNG‐IUS vs non‐intrauterine progestogen | OR 2.13 [1.33, 3.43] | 3 studies · 428 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Withdrawal secondary to adverse effects LNG‐IUS vs non‐intrauterine progestogen | OR 0.41 [0.12, 1.35] | 4 studies · 360 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Satisfaction with treatment LNG‐IUS vs non‐intrauterine progestogen | OR 5.28 [2.51, 11.1] | 2 studies · 202 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
LNG compared to no treatment for endometrial hyperplasia
Population: women with endometrial hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regression of EH ‐ Short LNG vs no treatment | OR 78.41 [22.86, 268.97] | 1 study · 190 participants | Low Downgraded: risk of bias |
Adverse effects associated with LNG‐IUS LNG vs no treatment | no estimate extracted | NR | No studies |
Hysterectomy LNG vs no treatment | no estimate extracted | NR | No studies |
Adverse effects associated with hormones LNG vs no treatment | no estimate extracted | NR | No studies |
Withdrawal secondary to adverse effects LNG vs no treatment | no estimate extracted | NR | No studies |
Satisfaction LNG vs no treatment | no estimate extracted | NR | No studies |
Cost of treatment LNG vs no treatment | no estimate extracted | NR | No studies |